Hydroxyethyl Starch 130/0.4

CHEMBL2108701 Phase 4 Одобрено Unknown
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This intravenous fluid expander is a large starch-based molecule given through a vein to increase blood volume in patients who have lost significant amounts of blood or fluid. Due to concerns about kidney injury and increased mortality in critically ill patients, its use has become restricted in many countries.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

This intravenous fluid expander is a large starch-based molecule given through a vein to increase blood volume in patients who have lost significant amounts of blood or fluid. Due to concerns about kidney injury and increased mortality in critically ill patients, its use has become restricted in many countries.

Yes, Hydroxyethyl Starch 130/0.4 is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108701. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.